Cardiovascular Disease in Dialysis Patients

Overview

Journal Nephrol Dial Transplant

Publisher Oxford University Press

Specialties General Surgery
Nephrology

Date 2018 Oct 4

PMID 30281132

Citations 224

Authors

Mario Cozzolino

Michela Mangano

Andrea Stucchi

Paola Ciceri

Ferruccio Conte

Andrea Galassi

Affiliations

Soon will be listed here.

Abstract

Cardiovascular disease (CVD) is a highly common complication and the first cause of death in patients with end-stage renal disease (ESRD) on haemodialysis (HD). In this population, mortality due to CVD is 20 times higher than in the general population and the majority of maintenance HD patients have CVD. This is likely due to ventricular hypertrophy as well as non-traditional risk factors, such as chronic volume overload, anaemia, inflammation, oxidative stress, chronic kidney disease-mineral bone disorder and other aspects of the 'uraemic milieu'. Better understanding the impact of these numerous factors on CVD would be an important step for prevention and treatment. In this review we focus non-traditional CVD risk factors in HD patients.

Citing Articles

Cardiovascular risk prediction in hemodialysis patients using the triglyceride-glucose index: a multicenter prospective cohort study.

Lee Y, Kang S, Kim D, Kim J, Jeong K, Kim Y Clin Kidney J. 2025; 18(3):sfaf016.

PMID: 40052161 PMC: 11883225. DOI: 10.1093/ckj/sfaf016.

Association between neutrophil percentage-to-albumin ratio and mortality in Hemodialysis patients: insights from a prospective cohort study.

Zhu J, Shi R, Li X, Liu M, Yu L, Bai Y BMC Nephrol. 2025; 26(1):112.

PMID: 40038629 PMC: 11881449. DOI: 10.1186/s12882-025-04027-0.

Cardiac arrhythmia and hypoglycaemia among individuals with and without diabetes receiving haemodialysis (the CADDY study): a Danish multicentre cohort study.

Kofod D, Diederichsen S, Bomholt T, Andersen M, Andersen A, Mannheimer E Diabetologia. 2025; .

PMID: 40019498 DOI: 10.1007/s00125-025-06388-5.

Effect of intradialytic exercise training on hemodialysis-induced myocardial stunning: a pilot-controlled trial.

Josse M, Patrier L, Cristol J, Isnard M, Grandperrin A, Turc-Baron C Clin Kidney J. 2025; 18(1):sfae352.

PMID: 40008351 PMC: 11852286. DOI: 10.1093/ckj/sfae352.

A randomized trial comparing medium cut-off membrane dialyzers with online hemodiafiltration for uremic toxins clearance in hemodialysis patients.

Lukkanalikitkul E, Kidkaem H, Phonrat M, Prathompong P, Anutrakulchai S Sci Rep. 2025; 15(1):5467.

PMID: 39953134 PMC: 11828957. DOI: 10.1038/s41598-025-89197-5.

References

Sun J, Axelsson J, Machowska A, Heimburger O, Barany P, Lindholm B . Biomarkers of Cardiovascular Disease and Mortality Risk in Patients with Advanced CKD. Clin J Am Soc Nephrol. 2016; 11(7):1163-1172. PMC: 4934843. DOI: 10.2215/CJN.10441015. View

Cozzolino M, Galassi A, Pivari F, Ciceri P, Conte F . The Cardiovascular Burden in End-Stage Renal Disease. Contrib Nephrol. 2017; 191:44-57. DOI: 10.1159/000479250. View

Meijers B, Bammens B, Moor B, Verbeke K, Vanrenterghem Y, Evenepoel P . Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int. 2008; 73(10):1174-80. DOI: 10.1038/ki.2008.31. View

Haugen E, Nath K . The involvement of oxidative stress in the progression of renal injury. Blood Purif. 1999; 17(2-3):58-65. DOI: 10.1159/000014377. View

Meijers B, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K . p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol. 2010; 5(7):1182-9. PMC: 2893077. DOI: 10.2215/CJN.07971109. View

Mahmoodi B, Matsushita K, Woodward M, Blankestijn P, Cirillo M, Ohkubo T . Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012; 380(9854):1649-61. PMC: 3993095. DOI: 10.1016/S0140-6736(12)61272-0. View

Sircana A, De Michieli F, Parente R, Framarin L, Leone N, Berrutti M . Gut microbiota, hypertension and chronic kidney disease: Recent advances. Pharmacol Res. 2018; 144:390-408. DOI: 10.1016/j.phrs.2018.01.013. View

Pavlovic D . The role of cardiotonic steroids in the pathogenesis of cardiomyopathy in chronic kidney disease. Nephron Clin Pract. 2014; 128(1-2):11-21. DOI: 10.1159/000363301. View

Vashistha T, Kalantar-Zadeh K, Molnar M, Torlen K, Mehrotra R . Dialysis modality and correction of uremic metabolic acidosis: relationship with all-cause and cause-specific mortality. Clin J Am Soc Nephrol. 2012; 8(2):254-64. PMC: 3562859. DOI: 10.2215/CJN.05780612. View

10.

Huang C, Moe O . Klotho: a novel regulator of calcium and phosphorus homeostasis. Pflugers Arch. 2011; 462(2):185-93. DOI: 10.1007/s00424-011-0950-5. View

11.

Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, Glorieux G . P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost. 2004; 92(1):140-50. DOI: 10.1160/TH03-07-0491. View

12.

Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C . Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005; 16(8):2449-55. DOI: 10.1681/ASN.2005010076. View

13.

Bover J, Evenepoel P, Urena-Torres P, Vervloet M, Brandenburg V, Mazzaferro S . Pro: cardiovascular calcifications are clinically relevant. Nephrol Dial Transplant. 2015; 30(3):345-51. DOI: 10.1093/ndt/gfv020. View

14.

Collado S, Coll E, Nicolau C, Azqueta M, Pons M, Cruzado J . Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function. BMC Nephrol. 2017; 18(1):290. PMC: 5590161. DOI: 10.1186/s12882-017-0701-8. View

15.

Pedraza-Chaverri J, Sanchez-Lozada L, Osorio-Alonso H, Tapia E, Scholze A . New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease. Oxid Med Cell Longev. 2016; 2016:6043601. PMC: 4939360. DOI: 10.1155/2016/6043601. View

16.

Kuzniewski M, Fedak D, Dumnicka P, Stepien E, Kusnierz-Cabala B, Cwynar M . Osteoprotegerin and osteoprotegerin/TRAIL ratio are associated with cardiovascular dysfunction and mortality among patients with renal failure. Adv Med Sci. 2016; 61(2):269-275. DOI: 10.1016/j.advms.2016.03.003. View

17.

Morena M, Cristol J, Bosc J, Tetta C, Forret G, Leger C . Convective and diffusive losses of vitamin C during haemodiafiltration session: a contributive factor to oxidative stress in haemodialysis patients. Nephrol Dial Transplant. 2002; 17(3):422-7. DOI: 10.1093/ndt/17.3.422. View

18.

Liabeuf S, Okazaki H, Desjardins L, Fliser D, Goldsmith D, Covic A . Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. Nephrol Dial Transplant. 2013; 29(7):1275-84. DOI: 10.1093/ndt/gft368. View

19.

Kaminski T, Pawlak K, Karbowska M, Mysliwiec M, Pawlak D . Indoxyl sulfate - the uremic toxin linking hemostatic system disturbances with the prevalence of cardiovascular disease in patients with chronic kidney disease. BMC Nephrol. 2017; 18(1):35. PMC: 5267373. DOI: 10.1186/s12882-017-0457-1. View

20.

Fox C, Matsushita K, Woodward M, Bilo H, Chalmers J, Lambers Heerspink H . Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012; 380(9854):1662-73. PMC: 3771350. DOI: 10.1016/S0140-6736(12)61350-6. View